Loading...
Market
Will AbbVie announce a major clinical trial for ALIA-1758 by Q4 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
ClinicalTrials.gov or AbbVie's official announcements
Story
AbbVie Acquires Privately Held Aliada Therapeutics for $1.4 Billion, Boosting Alzheimer's Focus with ALIA-1758
Oct 28, 2024, 12:11 PM
AbbVie Inc. has announced the acquisition of privately held Aliada Therapeutics for $1.4 billion in cash. This strategic move aims to bolster AbbVie's focus on Alzheimer's disease and its neuroscience pipeline. The acquisition includes Aliada's lead compound, ALIA-1758, and novel blood-brain barrier technology. The deal represents a significant return on investment for venture capital, with an initial investment of $33 million yielding $1.4 billion.
View original story
Similar markets
Q4 2024 • 25%
Q1 2025 • 25%
Q2 2025 • 25%
Q3 2025 • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Acquisition of another company • 25%
Launch of a new drug • 25%
Restructuring or cost-cutting measures • 25%
Other strategic move • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Q1 2025 • 25%
Q2 2025 • 25%
Q3 2025 • 25%
Q4 2025 • 25%